Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback